The phase 2 trial aimed to investigate the utility of uMRD profiling in predicting recurrence and assessing response to nadofaragene firadenovec therapy in BCG-unresponsive NMIBC patients. The primary endpoint was to determine RFS. Researchers noticed that uMRD offers the potential for tailored treatment strategies in bladder cancer trials. Urinary minimal residual disease (uMRD) […]...
Trusted insights straight to your inbox and get the latest updates from OncWeekly
Advertisement
Background Immune checkpoint blockade targeting the adaptive immune system has revolutionized the treatment of cancer. Despite impressive clinical benefits observed, patient subgroups remain non-responsive underscoring the necessity for combinational therapies harnessing additional immune cells. Natural killer …
Background Tertiary lymphoid structures (TLSs) are thought to stimulate antitumor immunity and positively impact prognosis and response to immune checkpoint blockade. In gastric cancers (GCs), however, TLSs are predominantly found in GC with poor prognosis and …
Background Patients with mismatch repair-deficient (MMRd) endometrial cancer (EC) can derive great benefit from immune checkpoint inhibitors (ICI). However not all responses and predictors of primary resistance are lacking. Methods We compared the immune tumor microenvironment of MMRd …
Background Fludarabine in combination with cyclophosphamide (FC) is the standard lymphodepletion regimen for CAR T-cell therapy (CAR T). A national fludarabine shortage in 2022 necessitated the exploration of alternative regimens with many centers employing single-agent bendamustine …
